Guidance

PCV (13-valent or 15-valent, adsorbed): patient group direction (PGD) template

PGD template to support the national pneumococcal polysaccharide conjugate vaccine (13-valent or 15-valent, adsorbed) (PCV) vaccination programme.

• From: UK Health Security Agency
• Published: 4 February 2016
• Last updated: 30 January 2024 — See all updates

Applies to England

Documents

PCV (13-valent or 15-valent, adsorbed): patient group direction (PGD) template

Ref: UKHSA gateway number GOV-15880

MS Word Document, 144 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template is to support the administration of pneumococcal polysaccharide conjugate vaccine (13-valent or 15-valent, adsorbed) (PCV13 or PCV15) to individuals from 12 weeks to under 2 years of age in accordance with the national immunisation programme.

The PCV PGD version 5.00 is valid from 28 February 2024 to 31 May 2026.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012. Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 4 February 2016
Last updated 30 January 2024 + show all updates

1. 30 January 2024

   Added version 5.00 - see page 3 for change history.

2. 17 February 2022

   Added version 04.00 - see change history on page 2.

3. 28 January 2020

   Added V03.00: updated PGD for the PCV 1+1 routine schedule for infants born on or after 1 Jan 2020.

4. 15 January 2019

   Added updated PGD template: validity from 6 weeks of age and addition of outbreak indication.

5. 10 January 2018

   Added notice of extension for PCV (13-valent, adsorbed) patient group direction.

6. 4 February 2016

   First published.